Ardelyx (NASDAQ:ARDX) Stock Jumps 4% – What’s Next?

Ardelyx, Inc. (NASDAQ:ARDX)’s stock price shot up 4% during trading on Wednesday. The stock traded as high as $3.25 and last traded at $3.2450. Approximately 2,591,013 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 4,275,936 shares. The stock had previously closed at $3.12.

Ardelyx News Roundup

Here are the key news stories impacting Ardelyx this week:

• Negative Sentiment: The lawsuit alleges that Ardelyx misrepresented or failed to disclose payer utilization-management barriers and prescription pull-through challenges that restricted patient access to IBSRELA. The complaints contend these issues slowed new-patient starts while the company maintained its 2025 sales guidance. Levi & Korsinsky Ardelyx class action notice
• Negative Sentiment: Another investor alert claims Ardelyx promoted combined peak-sales potential of approximately $1.75 billion for IBSRELA and XPHOZAH despite allegedly known access restrictions. The complaint points to the company’s subsequent reduction of 2026 guidance and withdrawal of its long-term XPHOZAH sales target as events that allegedly harmed shareholders. These are allegations and have not been proven in court. ARDX shareholder alert
• Neutral Sentiment: The reported class period runs from January 13, 2025, through August 6, 2026. Investors have until November 16, 2026, to seek appointment as lead plaintiff. The numerous announcements from Rosen, Kaplan Fox, Bronstein Gewirtz & Grossman, Robbins, Faruqi & Faruqi, Levi & Korsinsky and other firms largely repeat this procedural information rather than announce a new business development.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ARDX shares. Zacks Research downgraded Ardelyx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. TD Cowen reduced their target price on Ardelyx from $13.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 7th. BTIG Research decreased their target price on Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Piper Sandler decreased their target price on Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. Finally, Citigroup lowered their price target on Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.90.

Ardelyx Price Performance

The company’s 50-day simple moving average is $3.62 and its two-hundred day simple moving average is $5.02. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.69.

Ardelyx (NASDAQ:ARDX) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $120.88 million during the quarter, compared to analysts’ expectations of $121.03 million. Ardelyx had a negative return on equity of 36.00% and a negative net margin of 12.35%. The company’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.08) EPS. As a group, equities research analysts forecast that Ardelyx, Inc. will post -0.20 EPS for the current fiscal year.

Insider Activity at Ardelyx

In related news, insider Laura Williams sold 10,739 shares of Ardelyx stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $41,452.54. Following the sale, the insider directly owned 367,456 shares in the company, valued at $1,418,380.16. The trade was a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael Raab sold 58,574 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total transaction of $226,095.64. Following the completion of the sale, the chief executive officer owned 1,619,792 shares in the company, valued at approximately $6,252,397.12. This trade represents a 3.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 126,059 shares of company stock valued at $486,588 over the last ninety days. Insiders own 5.30% of the company’s stock.

Institutional Trading of Ardelyx

Large investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in shares of Ardelyx in the 2nd quarter worth $119,874,000. Jupiter Topco LLC purchased a new stake in Ardelyx in the 2nd quarter worth $27,043,000. AIGH Capital Management LLC purchased a new position in Ardelyx in the 2nd quarter worth approximately $16,320,000. Bank of America Corp DE purchased a new position in shares of Ardelyx in the second quarter worth $11,034,000. Finally, Rubric Capital Management LP bought a new position in shares of Ardelyx during the 1st quarter valued at about $11,147,000. 58.92% of the stock is currently owned by institutional investors.

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal conditions. The company’s products are designed to act locally in the gastrointestinal tract to address diseases involving phosphate, sodium, and other electrolytes.

Ardelyx’s primary products include XPHOZAH (tenapanor), an oral treatment approved in the United States to reduce intestinal phosphate absorption in adults with chronic kidney disease on dialysis who have hyperphosphatemia, and IBSRELA (tenapanor), an oral therapy approved for the treatment of irritable bowel syndrome with constipation in adults.